Clinical and Imaging Findings of 427 Hospitalized Patients with COVID-19 in Northeast of Iran

Background: Since December 2019, the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged the world. In this descriptive study, we aim to share the clinical information of 427 Iranian COVID-19 patients. Methods: The different information on COVID-19 patients who were hospitalized from 24 February 2020 to 1 April 2020 was analyzed using R software. The patients were categorized into two groups as non-severe or severe and survivor or non-survivor cases. Outcomes of the cases were followed up until one month after the time of admission. Findings: Overall, the median age of the patients was 53 with a difference of ten years between two categories in each group. Among patients, 50·8% were males who had worse outcomes than female patients. Cough (72·8%), fever (69·3%), and dyspnea (64·0%) were the most common symptoms. There were more underlying comorbidities in the group of severe (73·5%) and non-survivor (77·5%) cases compared to the non-severe (53·6%) and survivor (44·1%) groups. Changes in the pattern of the parameters of complete blood counts including lymphopenia (227/333; 68·2%) were the most prominent findings. Factors associated with the liver and kidney damage were significantly increased in patients, especially in non-survivor cases. Around 90% of the COVID-19 patients had at least one abnormality in the chest CT scans including simultaneously both crazy paving and consolidation patterns (27·1%), followed by the ground-glass opacity (24·7%). Interpretation: According to the results, the patients' age, underlying comorbidities, percentage of SpO2, and blood laboratory findings at the time of admission may indicate the progression of the disease in the coming days. Funding Statement: The Golestan University of Medical of Sciences, Iran. Declaration of Interests: The authors declare no competing interests. Ethics Approval Statement: The ethics committee of Golestan University of Medical Sciences approved the study (IR.GOUMS.REC.1398.383).